Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Alltrna logo — The world’s first transfer RNA (tRNA) platform company. We a...

Alltrna

The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potential within #tRNA.

Founded 2018 United States Cambridge, United States 49 employees Series B Total: $159.00M Biotechnology, Health Care +1

General Information

Company Name Alltrna
Founded Year 2018
Location United States Cambridge, United States
Employees 49
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Alltrna. To contact Alltrna, visit alltrna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Alltrna compare?

A PDF of Alltrna and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Alltrna soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Alltrna

Alltrna, founded in 2018 at Flagship Labs, is pioneering the use of transfer RNA (tRNA) to unlock vast therapeutic potentials in the field of biotechnology and health care. As the world’s first tRNA platform company, its mission is to advance tRNA therapeutics that can regulate the protein universe and address diseases driven by genetic mutations.

Utilizing its proprietary machine learning tools, Alltrna has meticulously mapped tRNA biology to design medicines that target disruptions in protein production, focusing on disease treatment and management. This innovative approach presents a groundbreaking opportunity to address both rare and common diseases associated with shared genetic underpinnings.

In August 2023, Alltrna secured a $109.00M Series B investment led by Flagship Pioneering, emphasizing investor confidence in the company’s potential to revolutionize therapeutic strategies from its base in the United States.

Business keywords: therapeutics, tRNA biology, genetic mutations, protein production, rare diseases, common diseases, machine learning tools, Flagship Labs, startup, innovation, biomedical research, precision medicine, genomics

Services & Products

Development of tRNA-based therapies
Engineering programmable tRNAs
Restoration of protein production
Treatment for stop codon diseases
Scaling genetic medicine

Target Customers

Patients with rare genetic diseases Medical research communities Healthcare providers Biopharmaceutical companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $109.00M 1
Flagship Pioneering
Flagship Pioneering
09 Aug 2023
Venture Round $50.00M 1
Flagship Pioneering
Flagship Pioneering
09 Nov 2021

Alltrna Alternatives & Competitors

View All Alternatives
Alltrna vs
Laronde
Laronde United States

Pioneering a completely novel translatable RNA platform - Endless RNA (eRNA)

Series B
44 employees
Biotechnology, Health and Wellness
Compare Alltrna vs Laronde
Alltrna vs
AIRNA
AIRNA United States

The next generation of RNA editing therapeutics

Series B
84 employees
Biotechnology, Health Care
Compare Alltrna vs AIRNA
Alltrna vs
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. United States

At Avidity, we are developing a new class of oligonucleotide-based therapies.

IPO
447 employees
Biotechnology, Health Care
Also compare with: Alltrna vs Tevard Biosciences Tevard Biosciences Alltrna vs HC Bioscience, Inc. HC Bioscience, Inc. View all alternatives

FAQ About Alltrna

The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potential within #tRNA.
Alltrna was founded in 2018.
Alltrna is headquartered in Cambridge, United States.
Alltrna operates in Biotechnology, Health Care and Health and Wellness. Its work centres on therapeutics, tRNA biology, genetic mutations and protein production. Its customers include Patients with rare genetic diseases, Medical research communities and Healthcare providers.
Alltrna has approximately 49 employees.
Alltrna has completed 2 funding rounds, raising a total of $159.00M. The latest funding stage is Series B.
Alltrna offers: Development of tRNA-based therapies, Engineering programmable tRNAs, Restoration of protein production, Treatment for stop codon diseases, Scaling genetic medicine.
Top alternatives and competitors to Alltrna include Laronde, AIRNA, Avidity Biosciences, Inc., Ascidian Therapeutics, Tevard Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alltrna and Laronde are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Alltrna, https://bouncewatch.com/company/alltrna, updated 26 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes